Glenmark ties up with South Korea's SCD for ophthalmic products
According to the pact, Glenmark and SCD will develop and commercialise six ophthalmic products in the US and Canada.
"Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorisations and commercialise the products in North America," the company said in a BSE filing.
Glenmark Pharmaceuticals President, North America & Global API, Robert Matsuk said, the agreement for these ophthalmic products is aligned with the company's strategy to strengthen its focus on complex generic formulations.
an Our strategic partnership with SCD supports our objective to expand the product offerings of our complex generic portfolio, he added.
According to the pact, Glenmark and SCD will develop and commercialise six ophthalmic products in the US and Canada.
"It is expected that Glenmark will file six abbreviated new drug applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products," it added.
Citing IMS sales figures, Glenmark said the U.S. brand sales for the six products were approximately USD 1.7 billion for the calendar year 2017.
New Delhi: Glenmark Pharmaceuticals has entered into an exclusive agreement with South Korea's Sam Chun Dang Pharm. Co. Ltd. (SCD) to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada.
"Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorisations and commercialise the products in North America," the company said in a BSE filing.
Glenmark Pharmaceuticals President, North America & Global API, Robert Matsuk said, the agreement for these ophthalmic products is aligned with the company's strategy to strengthen its focus on complex generic formulations.
an Our strategic partnership with SCD supports our objective to expand the product offerings of our complex generic portfolio, he added.
According to the pact, Glenmark and SCD will develop and commercialise six ophthalmic products in the US and Canada.
"It is expected that Glenmark will file six abbreviated new drug applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products," it added.
Citing IMS sales figures, Glenmark said the U.S. brand sales for the six products were approximately USD 1.7 billion for the calendar year 2017.
Read Also: Glenmark launches hair loss treatment Nourkrin in Russia
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd